Payment overview · 2025
General Payments
$1,127.69
48 reported records · 11 companies
Healthcare provider profile · identity verified
Sunil Shah, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · OAK LAWN, IL · NPI 1275517211
Verified facts
What the public records show
CMS Open Payments records show Sunil Shah, D.O. received $1,127.69 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Ozempic, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $439.50 | 39.0% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.56 | 16.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.90 | 9.8% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $95.09 | 8.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.90 | 6.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.82 | 5.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.73 | 5.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.59 | 3.7% | 2 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $24.03 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.37 | 1.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.20 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,127.69 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $364.92 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $176.44 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $151.55 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $122.67 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $109.90 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $74.90 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $69.69 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.82 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.73 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.03 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 117 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 759 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 563 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 68 |
| Omeprazole | Omeprazole | 444 | 87 |
| Lisinopril | Lisinopril | 408 | 97 |
| Metformin Hcl | Metformin Hcl | 341 | 71 |
| Gabapentin | Gabapentin | 315 | 77 |
| Simvastatin | Simvastatin | 310 | 60 |
| Losartan Potassium | Losartan Potassium | 294 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 41 |
| Montelukast Sodium | Montelukast Sodium | 202 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 82 |
| Glipizide | Glipizide | 192 | 36 |
| Chlorthalidone | Chlorthalidone | 188 | 49 |
| Potassium Chloride | Potassium Chloride | 173 | 24 |
| Carvedilol | Carvedilol | 165 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 164 | 54 |
| Mirtazapine | Mirtazapine | 156 | 43 |
| Famotidine | Famotidine | 148 | 33 |
| Prednisone | Prednisone | 145 | 104 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 41 |
| Furosemide | Furosemide | 136 | 37 |
| Levetiracetam | Levetiracetam | 131 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 30 |
| Allopurinol | Allopurinol | 125 | 18 |
| Naproxen | Naproxen | 121 | 38 |
| Eliquis | Apixaban | 117 | 19 |
| Warfarin Sodium | Warfarin Sodium | 116 | 22 |
| Sertraline Hcl | Sertraline Hcl | 110 | 12 |
| Ibuprofen | Ibuprofen | 107 | 44 |
| Vascepa | Icosapent Ethyl | 107 | 13 |
| Januvia | Sitagliptin Phosphate | 99 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 29 |
| Meloxicam | Meloxicam | 91 | suppressed |
| Fenofibrate | Fenofibrate | 89 | 16 |
| Ezetimibe | Ezetimibe | 85 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 23 |
| Donepezil Hcl | Donepezil Hcl | 74 | suppressed |
| Finasteride | Finasteride | 74 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | suppressed |
| Valsartan | Valsartan | 71 | suppressed |
| Tradjenta | Linagliptin | 70 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 66 | 20 |
| Fenofibrate | Fenofibrate,micronized | 65 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 64 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 15 |
| Buspirone Hcl | Buspirone Hcl | 58 | 18 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | 13 |
| Clonidine Hcl | Clonidine Hcl | 56 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Topiramate | Topiramate | 54 | 11 |
| Bumetanide | Bumetanide | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 11 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 52 | suppressed |
| Torsemide | Torsemide | 52 | suppressed |
| Spironolactone | Spironolactone | 51 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Acetazolamide Er | Acetazolamide | 48 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 47 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 18 |
| Nifedipine Er | Nifedipine | 45 | 15 |
| Digoxin | Digoxin | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Klor-Con M20 | Potassium Chloride | 40 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 11 |
| Azithromycin | Azithromycin | 38 | 32 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Nystatin | Nystatin | 29 | 17 |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 13 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | 11 |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pure Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,127.69 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, CAPLYTA, COBENFY, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, LINZESS, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZENPEP | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error